Clinical Trial Update: A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) [Phase 3]

View source ↗

Summary

This update concerns a Phase 3 study evaluating the long-term safety and efficacy of Donidalorsen for prophylaxis in hereditary angioedema; the trial is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Donidalorsen (antisense oligonucleotide targeting prekallikrein)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Hereditary Angioedema | Phase 3 | Status: ACTIVE_NOT_RECRUITING